Riskpilot← Back to searchSign inGet full accessBIOPHARMA HOLDING ApS
APSIn liquidationCVR 35206086Slotsmarken 12, 1.Activities of holding companies · NACE 6421Est. 20131 employees
Revenue 2024
DKK 921K
-3% vs 2023
EBITDA margin
-1.7%
-142% vs 2023
Equity ratio
93.0%
Financial strength
Net profit 2024
DKK -3,7M
+82% vs 2023
| Revenue | DKK 921K | -3% |
| EBITDA | DKK -16K | -142% |
| Net profit | DKK -3,7M | +82% |
| Total assets | DKK 3,1M | -97% |
| Equity | DKK 2,9M | -97% |
| Employees | 1 | — |
Legal name
BIOPHARMA HOLDING ApS
CVR number
35206086
Legal form
Anpartsselskab
NACE code
6421 · Activities of holding companies
Founded
15. marts 2013
Share capital
DKK 80.000
Employees
1 (FTE)
VAT registered
No
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Company purpose
Selskabets formål er at drive virksomhed med holdingvirksomhed og enten direkte eller gennem dattervirksomheder samt have aktiviteter blandt andet men ikke udelukkende indenfor udvikling og repositionering af lægemiddelkandidater, samt al virksomhed, som efter direktionens skøn er beslægtet hermed.
Address
Slotsmarken 12, 1.
Phone
+4540940708
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 183 | 149 | 379 | 298 | 405 | 385 | 591 | 704 | 1.194 | 950 | 921 |
| Staff expenses | -0 | -0 | -0 | -1.918 | -381 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -52 | -1.732 | -2.457 | -2.147 | -493 | -123 | -182 | -71 | 82 | 380 | 38 | -16 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -52 | -1.732 | -2.457 | -2.147 | -493 | -123 | -182 | -71 | 82 | 380 | 38 | -16 |
| Net financials | 258.470 | 12.381 | -197.876 | -4.704 | -7.661 | 1.496 | 24.548 | 1.567 | 11.934 | -30.102 | -20.615 | -3.690 |
| Profit before tax | 258.468 | 10.648 | -200.336 | -6.852 | -8.154 | 1.373 | 24.366 | 1.495 | 12.016 | -29.722 | -20.576 | -3.706 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 27 |
| Net profit | 258.419 | 10.648 | -200.333 | -6.852 | -8.154 | 1.373 | 24.366 | 1.495 | 12.016 | -29.722 | -20.576 | -3.733 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 323.719 | 336.383 | 134.542 | 128.989 | 119.707 | 121.400 | 149.245 | 151.158 | 167.313 | 137.803 | 115.939 | 3.140 |
| Equity | 323.719 | 334.367 | 134.034 | 127.182 | 119.028 | 120.401 | 144.767 | 146.262 | 158.278 | 128.556 | 107.980 | 2.921 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 2.016 | 509 | 1.807 | 679 | 999 | 4.478 | 4.896 | 9.035 | 9.247 | 7.960 | 219 |
| Total debt | 0 | 2.016 | 509 | 1.807 | 679 | 999 | 4.478 | 4.896 | 9.035 | 9.247 | 7.960 | 219 |
EBITDA margin
-1.7%
This company
15.8%
Market median
-111% vs market
20132024
Equity ratio
93.0%
This company
38.2%
Market median
+143% vs market
20132024
Return on equity
-127.8%
This company
18.4%
Market median
-795% vs market
20132024
Net profit margin
-405.1%
This company
8.1%
Market median
-5101% vs market
20132024
Asset turnover
0.29×
This company
1.12×
Market median
-74% vs market
20132024
Debt / equity
0.07×
This company
0.62×
Market median
+89% vs market
20132024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-03-15 – 2013-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HL Management | Management | 2013 | — | — |
JJ Unofficial title | Unofficial title | 2025 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
FINANSMANAGEMENT ApS | Company | 50.0% | 50.0% | 2015 |
DKA CONSULT ApS | Company | 33.3% | 0.0% | 2013 |
BIOPHARMA HOLDING ApS | Company | 0.0% | 33.3% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
DKA CONSULT ApS
BIOPHARMA HOLDING ApS Board members of BIOPHARMA HOLDING ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Henrik Lasse Lindblad | Management | 0 companies |
| Jens Jacob Aaes | Unofficial title | 0 companies |